As of 2024-07-27, the EV/EBITDA ratio of Acceleron Pharma Inc (XLRN) is -41.25. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Acceleron's latest enterprise value is 10,456.47 mil USD. Acceleron's TTM EBITDA according to its financial statements is -253.46 mil USD. Dividing these 2 quantities gives us the above Acceleron EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.7x - 22.9x | 17.9x |
| Forward P/E multiples | 19.1x - 24.5x | 21.4x |
| Fair Price | (74.69) - (90.56) | (77.02) |
| Upside | -141.8% - -150.7% | -143.1% |
| Date | EV/EBITDA |